Abbott’s Hep C Drug Trio Cures Most in a Few Months | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Hepatitis C Drug Labeling Update

Back to News Homepage
Next

Hepatitis B Virus Destroyed by Inovio's Vaccine

Abbott’s Hep C Drug Trio Cures Most in a Few Months

The Editors at Hepatitis Central
November 15, 2012

Print this page

In a mid-stage trial, Abbott’s all-oral drug combo for Hepatitis C posted cure rates in the 90th percentile – even in previous non-responders.

UPDATE 2-Abbott hepatitis C drugs bring high cure rates in trial

  • High cure rates seen in patients treated 8 or 12 weeks
  • 93 pct who failed prior drugs cured after 12 weeks
  • 97 pct of newly treated patients deemed cured after 12 weeks
  • One percent discontinue treatment due to side effects (Adds 100 pct cure rates with Gilead drug in small trial)

By Ransdell Pierson

Nov 10 (Reuters) – A trio of oral medicines from Abbott Laboratories Inc to treat hepatitis C produced unprecedented cure rates in patients who had failed to benefit from standard treatment, as well as very high cure rates for newly treated patients, Abbott said on Saturday.

Detailed data from the mid-stage trial, called Aviator, were released Saturday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.

Continue reading this entire article:
http://www.reuters.com/article/2012/11/10/health-liver-abbott-idUSL1E8MA0VL20121110

9 Comments
Share
Share
Previous

Hepatitis C Drug Labeling Update

Back to News Homepage
Next

Hepatitis B Virus Destroyed by Inovio's Vaccine

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.